Zantac Lawsuit Payouts and Settlement Costs Cause Concerns Among Drug Company Investors
Approaching trial dates and analyst estimates that Zantac settlement payouts may reach $45 billion caused investor stock selloff this week
Approaching trial dates and analyst estimates that Zantac settlement payouts may reach $45 billion caused investor stock selloff this week
Lawsuit over chronic kidney disease from Nexium will be the first of more than 13,500 claims to go before a jury when trial begins in November 2022
First case to go to trial involves a Nexium lawsuit filed over a kidney disease diagnosis, which is expected to be followed by additional bellwether trials in March 2023 and April 2023
Court has pushed back the start of first California Zantac trials, with cases set to go before juries starting in February, May, August and October 2023
Motions were filed in advance of hearings scheduled for September 2022, at which time the Court will weigh the reliability of expert testimony on the link between Zantac and cancer.
MDL Judge will decide at a series of Daubert hearings which expert testimony about the link between Zantac and cancer will be admissible at trial
Large groups of Nexium lawsuits, Prilosec lawsuits and other claims involving kidney damage following use of popular heartburn drugs will be selected each quarter, and prepared for trial
After first round of bellwether trials begin in October 2022, a second round of kidney damage lawsuits will be prepared to go before juries by late next year.
Reports suggest more than 100,000 claims have been registered in the Zantac MDL, alleging various cancers were caused by the recalled heartburn pills
The first Nexium bellwether lawsuit is scheduled to go before a jury in October